Using Propranolol for Patients with Gastrointestinal Tumors Before Surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of perioperative propranolol, a beta-blocker, on patients with surgically resectable primary gastrointestinal tumors, specifically gastric and colorectal cancers. The study is designed as a single-center, randomized controlled pilot exploratory trial involving 40 patients, who will be divided into treatment and control groups. The treatment group will receive propranolol for 10-14 days prior to surgery, while the control group will not receive the medication. The study aims to evaluate the safety and efficacy of propranolol, as well as its potential to alleviate psychological stress during the perioperative period, alongside a multi-omics analysis of clinical samples to understand the anti-tumor immune response.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Surgically resectable primary gastric cancer and colorectal cancer;
2. Age greater than 18 years old and less than 65 years old;
3. Negative pregnancy test for women of childbearing age;
4. ECOG score ≤2;
5. Signed informed consent.
6. Resting blood pressure greater than 100/60mmHg, heart rate greater than 60 beats per minute.

Exclusion Criteria：

1\) Pregnant or breastfeeding women, or women with pregnancy plans within six months; 2) Patients with absolute or relative contraindications to propranolol:

1. Pathological sinus node syndrome;
2. Sinus bradycardia (less than 60 beats/minute);
3. First, second or third degree AV block;
4. Resting blood pressure less than 100/60 mmHg;
5. untreated pheochromocytoma;
6. untreated thyroid disease;
7. Patients on dihydropyridine or non-dihydropyridine calcium channel blockers (e.g., diltiazem, verapamil, nifedipine, amlodipine);
8. Severe peripheral vascular disease (intermittent claudication);
9. Patients on antiarrhythmic drugs (e.g., amiodarone, sotalol, digoxin);
10. Patients with renal insufficiency (defined as creatinine clearance greater than 0.15 mmol/L);
11. Patients with hepatic insufficiency: AST or ALT or ALP \> 2.5 times the upper limit of normal (ULN), bilirubin \> 1.5 times the ULN, ALP \> 2.5
12. Patients using colistin, digoxin, rizatriptan, cimetidine, hydralazine, guanethidine, or ergotamine.
13. Patients with a history of major depressive episodes; 3) Patients who have undergone surgery for GI tumors within the previous six months; 4) Patients receiving neoadjuvant chemotherapy prior to planned gastrointestinal tumor resection; 5) patients using conventional anxiolytic drugs (e.g. benzodiazepines), alpha-adrenergic agonists (e.g. colistin); 6) Patients using selective or non-selective β-adrenergic inhibitors (e.g., propranolol, metoprolol, atenolol, sotalol) within the last three months; 7) Patients with a history of stroke; 8) Patients with moderate or severe asthma, defined as requiring hospitalization or oral steroid therapy; (9) Those who, in the opinion of the physician, have other reasons for not being included in the treatment.

Where it's running

• Huashan Hospital, Fudan University
  Shanghai, Shanghai Municipality, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BL-M08D in patients with digestive tract and other solid tumors

  A early-stage study to see if BL-M08D1 can be safely given and help people with advanced digestive tract cancers and other solid tumors.

  Recruiting Phase 1/2 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07780318

• BL-ARC002 in patients with advanced solid tumors

  This study tests BL-ARC002 to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT07763652

• Gastrointestinal cancer screening using a multi-target detection model

  A randomized trial tests whether a combined blood and stool screening approach can reduce 5-year gastrointestinal cancer deaths compared with standard routine observation.

  Recruiting at 6 sites Xijing Hospital · Zhaoqing, Guangdong and 5 other locations · NCT07712107

• SKB571 in Gastrointestinal Tumors

  A Phase 2, open-label study tests SKB571 in adults with gastrointestinal tumors to see if it is safe and may help shrink tumors.

  Recruiting at 25 sites Phase 2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Chongqing, Chongqing Municipality and 25 other locations · NCT07564466

• KQB198 plus imatinib for first-line advanced or metastatic GIST

  This Phase 2 test will see if adding the experimental drug KQB198 to imatinib helps people with advanced or metastatic GIST who are starting first-line treatment.

  Recruiting at 17 sites Phase 2 Kumquat Biosciences Inc. · Los Angeles, California and 16 other locations · NCT07406633

• BL-M24D1 treatment for advanced gastrointestinal and other solid tumors

  This trial will test BL-M24D1 in adults with locally advanced or metastatic gastrointestinal and other solid tumors to see if it is safe, tolerated, and shows early signs of anti-tumor activity.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07279428

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.